loading...

2018-Brisbane-Immunotherapy-Logo-x3.1
  • HOME
  • EVENT INFO
    • Conference Co-hosts
    • 2019 Organising Committee
    • Registration information
    • Related Meetings
  • Program
  • Public Forum
  • Speakers
    • International Speakers
    • National Speakers
  • Register
  • SPONSOR AND EXHIBIT
    • Become a Sponsor/Exhibitor
  • VISITOR INFO
    • Visa information
    • Travel, transport and accommodation
    • Pre and Post Conference Touring
  • CONTACT

The program below may still be subject to further changes as arrangements with speakers are finalised. 

THURSDAY - 23rd May 2019

07:30-17:00 Registration Desk Open

Location: Boulevard Auditorium Foyer

08:30 Welcome and Acknowledgements

Location: Boulevard Auditorium

08:30-8:40
Introduction and Acknowledgements
Associate Professor Antiopi Varelias

8:40-8:50
Welcome and Conference Objectives
Professor David Whiteman

08:50-09:00
Welcome to Brisbane
Hon Dr Steven Miles, the Minister for Health and Minister for Ambulance Services in the Palaszczuk Labor Government

09:00-10:00 Session I: Keynote Lecture

Location: Boulevard Auditorium

Chair: Professor Ranjeny Thomas

Professor Marco Colonna, Department of Pathology and Immunology, Washington University, St. Louis

10:00-10:30 Morning Tea

Location: Boulevard Auditorium Foyer

10:30-12:05 Session II: Immunotherapy for autoimmune diseases

Location: Boulevard Auditorium

Chair: Professor Ranjeny Thomas

10:30-11:00
Professor Qizhi Tang, Director, UCSF Transplantation Research Lab, Department of Surgery, University of California, San Francisco - Translating regulatory T cell therapy to the clinic

11:00-11:20
Dr Emma Hamilton-Williams, The University of Queensland Diamantina Institute - Antigen-specific immunotherapy for type 1 diabetes

11:20-11:35
Dr Anne-Sophie Bergot, The University of Queensland Diamantina Institute - Regulatory T cells induced following single antigen immunotherapy suppress islet-specific T cell responses to multiple antigens and protect from autoimmune diabetes

11:35-11:50
Pascale Wehr, The University of Queensland Diamantina Institute - Arthritogenic clonally-expanded autoantigen-specific CD4+ T cells are a target for prevention of autoimmune arthritis

11:50-12:05
Aimee Hanson, The University of Queensland Diamantina Institute - T-cell receptor immunosequencing reveals disease-associated clonal expansions and altered repertoire diversity in ankylosing spondylitis patients

12:05-13:15 Lunch

Location: Boulevard Auditorium Foyer

13:15-14:50 Session III: Immunotherapy and the tumour microenvironment

Location: Boulevard Auditorium

Chair: Dr Tobias Bald

13:15-13:45
Professor Matthew Krummel, Department of Pathology, University of California San Francisco (UCSF) - Disseminating Tumor-Self via A Synaptic Cellular ‘Mancala`

13:45-14:05
Associate Professor Thomas Gebhardt, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity - Tissue-resident memory T cells promote melanoma-immune equilibrium in skin

14:05-14:20
Dr Ailin Lepletier, QIMR Berghofer Medical Research Institute - Tumor-intrinsic CD155 expression limits sensitivity to anti-PD-1 therapy in advanced metastatic melanoma

14:20-14:35
Diana Canals-Hernaez, The Biomedical Research Centre, University of British Columbia, Canada - Podocalyxin is a therapeutic target in carcinoma

14:35-14:50
Alvaro Sanchez-Herrero, Institute of Health & Biomedical Innovation, Queensland University of Technology - Tissue engineering of an orthotopic humanised bone-organ as a platform for preclinical multiple myeloma research

14:50-15:30 Afternoon Tea

Location: Boulevard Auditorium Foyer

15:30-17:00 Session IV: Adoptive immunotherapies

Location: Boulevard Auditorium

Chair: Associate Professor Corey Smith and Dr Ashleigh Poh

15:30-16:00
Dr Emily Blyth, Westmead Clinical School, The Westmead Institute for Medical Research and Westmead Hospital - BMT Cell Therapies, Sydney - The way forward for antigen-specific T cells for immune reconstitution – stem cell donors or third party cell banks?

16:00-16:20
Dr Paulo Martins, Tumour Immunology Group, QIMR Berghofer Medical Research Institute - Serotherapy prevents cytomegalovirus reactivation after transplantation

16:20-16:35
Associate Professor Corey Smith, QIMR Berghofer Medical Research Institute - Restructuring of the TRBV landscape is coincident with clinical response to T cell therapy in transplant recipients

16:35-16:50
Simone Minnie, QIMR Berghofer Medical Research Institute - Stem cell transplantation establishes T cell-dependent myeloma immune-equilibrium that can be enhanced with immunotherapy

16:50-17:05
Dr Matthias Braun, QIMR Berghofer Medical Research Institute - Loss of DNAM-1 on CD8+ T cells: a novel immune escape mechanism

17:00-19:00 Poster Session I / Welcome Reception

Location: Boulevard Auditorium Foyer

Join us for welcome refreshments and the first poster session.

19:00-20:00 Public Forum

Location: Boulevard Auditorium

Sponsored by Icon Group Australia

Join us for a public forum open to conference delegates and members of the general public to attend. This is a free session.

For more details and to register, visit the event website.

FRIDAY - 24th May 2019

08:00-17:00 Registration Desk Open

Location: Boulevard Auditorium Foyer

08:30-09:30 Session V: Keynote Lecture

Location: Boulevard Auditorium

Chair: Professor Mark Smyth

Professor Matthew Krummel, Department of Pathology, University of California San Francisco (UCSF) - Imaging a World Beyond Checkpoint:  Archetypes of Immunity in Tumors and Beyond

09:30-09:50 Session VI: Adenosine: the new kid on the block

Location: Boulevard Auditorium

Chair: Associate Professor Michele Teng

09:30-09:50
Associate Professor John Stagg, CRCHUM and Institute of Cancer, University of Montreal - Targeting CD73 in cancer immunotherapy: beyond adenosine inhibition

09:50-10:10
Dr Courtney Beers, Vice President, Immunology, Tizona Therapeutics, San Francisco - Targeting CD39 with a First-in-Class Inhibitory Antibody Prevents ATP Processing and Increases T-Cell Activation

10:10-10:30
Dr Pam Holland, Vice President, Cancer Biology, Surface Oncology, Cambridge - Targeting the Adenosine Axis to Treat Cancer

10:30 Morning Tea

Location: Boulevard Auditorium Foyer

11:00-12:30 Session VII: Immunogenomics

Location: Boulevard Auditorium

Chair: Dr Nic Waddell

11:00-11:30
Dr Jinmiao Chen, Single-Cell Computational Immunology (SCCI), Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore - Single-cell analysis of crosstalk between tumor, immune cells and pathogens in gastric cancer

11:30-11:45
Dr Ann-Marie Patch, Head of Clinical Genomics Group, QIMR Berghofer Medical Research Institute - Bridging the fields of cancer genomics and Immunotherapy

11:45-12:00
Dr Andreas Behren, Olivia Newton-John Cancer Research Institute - The immunopeptidome of melanoma

12:00-12:15
Dr Simon Junankar, Garvan Institute of Medical Research - DNA barcoding demonstrates immuno-editing of metastatic breast cancer cells at the clonal level

12:15-12:30
Dr Jessica Engel, QIMR Berghofer Medical Research Institute - Mapping the Development of Gut Pathogenic CD4+ T-cells during Graft-versus-Host Disease using single-cell RNA-seq

12:30-13:30 Lunch

Location: Boulevard Auditorium Foyer

13:30-15:05 Session VIII: Innate immune cells in cancer immunotherapy

Location: Boulevard Auditorium

Chair: Dr Tobias Bald

13:30-14:00
Dr Jan Böttcher, Institute of Molecular Immunology and Experimental Oncology, Technical University Munich - The role of cDC1/NK cell communication within the tumor microenvironment for anti-cancer immunity

14:00-14:20
Dr Tatyana Chtanova, Innate and Tumour Immunology, Garvan Institute of Medical Research - Innate immune cells in cancer: Teaching neutrophils new tricks

14:20-14:35
Juming Yan, QIMR Berghofer Medical Research Institute - Title TBC

14:35-14:50
Associate Professor Eynav Klechevsky, Washington University School of Medicine, St. Louis - Upstream activation of anti-tumor immunity via human dendritic cell subsets

14:50-15:05
Amanda Oliver, Peter MacCallum Cancer Centre - Tissue-specific differences in the tumour microenvironment and their influence on immunotherapeutic response

15:05-15:30 Afternoon Tea

Location: Boulevard Auditorium Foyer

15:30-16:00 Session IX: The Microbiome: an emerging universe

Location: Boulevard Auditorium

Chair: Associate Professor Antiopi Varelias

15:30-16:00
Dr Beth Helmink, Department of Surgical Oncology and Genomic Medicine, University of Texas MD Anderson Cancer Centre - Bringing concepts to clinic:  the gut microbiome and the response to and toxicity of immune checkpoint blockade in melanoma

16:00-16:20
Professor Emad El-Omar, Director, Microbiome Research Centre, St George and Sutherland Clinical School, University of New South Wales - The role of the microbiome in GI cancer

16:20-16:40
Dr Nadeem Kaakoush, Head of Host-Microbiome Interactions Group, School of Medical Sciences, University of New South Wales, Sydney - Microbiome manipulation through faecal microbiota transplantation therapy

16:40-18:05 Session X: Immunotherapy and infectious diseases

Location: Boulevard Auditorium

Chair: Dr Janin Chandra

18:40-17:10
Professor Man-Wah Tan, Infectious Diseases Therapeutic Area, Genentech, San Francisco, California - Harnessing nature’s gift: antibody and antibody-antibiotic conjugates to treat bacterial infections

17:10-17:30
Dr Keith Chappell, School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland - Rapid response pipeline for stabilized subunit vaccines

17:30-17:50
Dr Christian Engwerda, QIMR Berghofer Medical Research Institute - Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of malaria and visceral leishmaniasis.

17:50-18:05
Dr Manisha Pandey, Institute for Glycomics, Griffith University - Immunotherapy with antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA humanized mice

18:05-19:30 Poster Session II / Light Refreshments

SATURDAY - 25th May 2019

08:00-14:00 Registration Desk Open

Location: Boulevard Auditorium Foyer

09:00-10:30 Session XI: Plenary Session: Neoadjuvant immunotherapy - a game changer?

Location: Boulevard Auditorium

Chair: Dr Elizabeth Ahern

09:00-10:00
Professor Christian Blank, Department of Medical Oncology & Division of Immunology, Netherlands Cancer Institute– Antoni van Leeuwenhoek Hospital, Amsterdam - Neoadjuvant Immunotherapy – the pathway to personalized immunotherapy in melanoma and beyond

10:00-10:30
Associate Professor Michele Teng, Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute - Neoadjuvant immunotherapy and surgery – a window of opportunity for tumor-specific T cell memory differentiation

10:30-11:00 Morning Tea

Location: Boulevard Auditorium Foyer

11:00-12:45 Session XII: CAR-T cells: Beyond blood cancers

Location: Boulevard Auditorium

Chair: Dr Siok Tey

11:00-11:30
Professor Stephen Gottschalk, Dept. of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Hospital - Engineering Lymphocytes for the Adoptive Immunotherapy of Solid Tumors

11:30-11:50
Professor Simon Barry, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide - Title TBC

11:50-12:05
Dr Blake Aftab, Preclinical and Translational Sciences, Atara Biotherapeutics - CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T cells – An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform

12:05-12:20
Professor Riccardo Dolcetti, The University of Queensland Diamantina Institute - Enhancing CAR-T cell immunotherapy against solid tumours by exploiting nanoemulsion-based indirect vaccination

12:20-12:35
Jessica Michie, Peter MacCallum Cancer Centre - Antagonism of IAPs enhances CAR T cell efficacy

12:45-14:00 Lunch

Location: Boulevard Auditorium Foyer

14:00-15:20 Session XIII: Clinical immuno-oncology

Location: Boulevard Auditorium

Chair: Dr Andrea Henden

14:00-14:20
Associate Professor Victoria Atkinson, School of Clinical Medicine, The University of Queensland and Medical Oncologist, Princess Alexandra and Greenslopes Private Hospitals, Brisbane - Modern Immunotherapy for advanced melanoma

14:20-14:40
Professor Sandro Porceddu, Director Radiation Oncology Research, Cancer Services, Princess Alexandra Hospital and Faculty of Medicine, University of Queensland - The evolution and role of immunotherapy in head and neck cancer

14:40-15:00
Professor Ken O’Byrne, Medical Oncologist, Princess Alexandra Hospital, Queensland University of Technology, Translational Research Institute - Title TBC

15:00-15:20
Dr Alistair Cook, Research Fellow, Faculty of Health and Medical Sciences, UWA Medical School, The University of Western Australia - Results of a phase 2 trial of DuRvalumab with first line chEmotherApy in Mesothelioma (DREAM)

15:20-15:50 Award Presentations and Closing Remarks

Location: Boulevard Auditorium

REGISTER NOW
DOWNLOAD PROGRAM AS PDF
Speakers

Speakers

Meet the amazing international and national line-up of  invited speakers for Brisbane Immunotherapy 2019.

Read more
Sponsorship

Sponsorship

Interested to support this conference. Download our prospectus and become a sponsor today.

Read more
Registration

Register Now

Early Bird Registration ends Friday 22 March 2019! Save $150 on Standard registration fees.

Online Registration

2019 Sponsors and Supporters

Miltenyi Biotec logo web
bd_3_rgb_lbg_1_5

Contact Us

E conferences@qimrberghofer.edu.au
T +61 7 3362 0397

QIMR Berghofer Medical Research Institute
Locked bag 2000
Royal Brisbane Hopsital QLD 4029

Sign up for Email updates

Receive  information including deadline reminders, speaker profiles, program changes and much more...

Sign up

©2018